Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2024 07:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development

Executive Management Team appointments contribute to Emergent’s transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04,...
October 23, 2024 07:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the...
October 08, 2024 17:32 ET | Source: Emergent BioSolutions

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

Ongoing support of the ‘White House Challenge to Save Lives from Overdose’ through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness,...
October 02, 2024 07:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility

GAITHERSBURG, Md., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it entered into a new credit agreement on September 30, 2024 providing for an...
September 26, 2024 08:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

GAITHERSBURG, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”) today announced that two contract options have been secured to procure additional treatment...
September 25, 2024 07:07 ET | Source: Emergent BioSolutions

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

GAITHERSBURG, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured approximately $400 million in orders in 2024 and 2025 associated with its...
September 13, 2024 06:45 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation

GAITHERSBURG, Md., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent” or the “Company”) today announced that it has entered into an agreement to resolve the...
September 12, 2024 08:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical...
September 03, 2024 07:08 ET | Source: Emergent BioSolutions

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the closing of a new credit facility agreement with Oak Hill Advisors for a term loan of...
August 30, 2024 08:16 ET | Source: Emergent BioSolutions

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

For the second year, Emergent is teaming up with pro football legend, Emmitt Smith, to educate communities on opioid risks and how to be prepared with NARCAN® Nasal SprayIn recognition of...